Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


50 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

PBT, PRANA BIOTECHNOLOGY LIMITED
plastic
post Posted: Apr 7 2019, 06:41 AM
  Quote Post


Posts: 10,109
Thanks: 299


Dog tucker indeed. But the hangers on got to fund their lifestyles and pay their mortgages in the interim.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Dec 13 2017, 03:14 AM
  Quote Post


Posts: 10,109
Thanks: 299


Huntingtons' breakthrough in the news. No news in the fact that it has nothing to do with PBT. PBT looking like dog tucker. Good only if you're a bit of a mongrel. Get to dine out on it again.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Sep 21 2017, 05:34 AM
  Quote Post


Posts: 10,109
Thanks: 299


A new benchmark for Alzheimers just got set overnight with ALNY and their Patisiran drug. If anyone thinks PBT is going to amount to anything now they are absolutely dreaming.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Dec 8 2014, 09:39 AM
  Quote Post


Posts: 10,109
Thanks: 299


While everyone here pumps PBT for reasons I can't figure out, the real progress in Alzheimers is being done at BIIB. The amount of market cap. this ann. put on is huge. If anything similar every happened to PBT that would truly be an amazing feat of accomplishment I must say.

QUOTE
Biogen Idec Inc. ( BIIB ) Is Soaring On Positive Alzheimer's Study Results


(RTTNews.com) - Biogen Idec Inc. ( BIIB ) announced interim phase 1b results Tuesday morning, which showed that its experimental treatment for Alzheimer's disease reduced amyloid plaques in the brain and showed positive effects on cognition.


Biogen Idec has gapped open sharply higher this morning and is now up 20.87 at $329.31 on above average volume. The stock has jumped to a 3-week high and has re-crossed both its 50 and 200-day moving averages.

For comments and feedback: contact editorial@rttnews.com



Read more: http://www.nasdaq.com/article/biogen-idec-...7#ixzz3LG54VZT2




--------------------
What did Uncle Mel do to us?
 
trader48
post Posted: May 5 2014, 08:17 AM
  Quote Post


Posts: 6


In Reply To: plastic's post @ May 5 2014, 07:53 AM

from Traderlilly - h/c

Meeting Coverage
Scans Rule Out Alzheimer's
Published: May 1, 2014 | Updated: May 2, 2014

By John Gever, Deputy Managing Editor, MedPage Today
Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania
save|AA
Action Points
Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
Florbetaben imaging has a high negative predictive value and appears to reliably exclude amyloid pathology in the differential diagnosis of dementia.
PHILADELPHIA -- Autopsy findings in 74 elderly individuals confirmed the accuracy of brain scans for beta-amyloid plaques conducted before they died -- and also showed that the patients' clinical diagnoses were frequently wrong, a researcher said here.

Among 57 patients in the cohort who had received diagnoses of Alzheimer's disease on the basis of clinical symptoms, 13 were found to have beta-amyloid plaque burdens too low to be consistent with the disease, either in post-mortem histopathology findings or in PET scans using the recently approved beta-amyloid plaque tracer florbetaben (Neuraceq) performed while the patients were still alive, according to Marwan Sabbagh, MD, director of Banner Sun Health Research Institute in Sun City, Ariz.

In the cohort overall, which also included three patients with Lewy body dementia, six with other dementias, and eight nondemented individuals, autopsy findings showed that the PET scans had 97.9% sensitivity for picking up amyloid plaques (95% CI 93.8%-100%) and 88.9% specificity (95% CI 77.0%-100%), Sabbagh told attendees at a late-breaking abstract session at the American Academy of Neurology's annual meeting.

He told MedPage Today that the 20% error rate in clinical Alzheimer's disease diagnosis was consistent with earlier studies.

Furthermore, these new findings demonstrate that amyloid PET scans, by ruling out Alzheimer's disease diagnosis in patients who would otherwise have received it, can alter patients' management and improve outcomes, Sabbagh said.

The question of whether amyloid PET scans with tracers such florbetaben -- other approved products include florbetapir (Amyvid) and flutemetamol (Vizamyl) -- inform clinical decision making was a key sticking point for the Centers for Medicare and Medicaid Services when it decided last year not to allow Medicare coverage except in research studies.

CMS argued that although the scans appeared to be accurate in ruling out Alzheimer's disease, there was no specific evidence that clinical management would be changed as a result.

The current study does not quite provide such evidence, Sabbagh acknowledged, but it does make it harder to imagine how the scans would not have that effect.

Still lacking, he said, was autopsy-confirmed diagnoses in the 13 patients misdiagnosed clinically with Alzheimer's disease. The data also didn't indicate how the PET scan results were incorporated into the patients' treatment.

But almost any other diagnosis would probably have led to a different management plan in those patients, he told MedPage Today. A finding of no amyloid plaque in a putative Alzheimer's disease patient should automatically prompt a search for other causes for the symptoms.

"If the patient has FTD (frontotemporal dementia), I'm not going to give cholinesterase inhibitors because they don't work," Sabbagh said.

Neill Graff-Radford, MD, of the Mayo Clinic in Jacksonville, Fla., who was not involved in the study, said he understood CMS' argument, but he agreed that the PET scans can't help but inform clinical management.

"Refining and being very accurate with the diagnosis is absolutely essential," he said. "Clinical diagnosis, even in very experienced hands, doesn't necessary correlate with the pathological diagnosis."

He pointed out that the scans are now being used to select patients for clinical trials of anti-amyloid Alzheimer's disease therapies precisely because they improve the diagnostic accuracy.

Study Details

 
plastic
post Posted: May 5 2014, 07:53 AM
  Quote Post


Posts: 10,109
Thanks: 299


If anyone wants to know if naked shorting is still freely available and in use on the ASX despite whatever law you wish to poke a stick at, look no further than PBT. That data didn't make one iota of difference to anything. A blind man could see it coming.



--------------------
What did Uncle Mel do to us?
 

Featured Stock Stories





plastic
post Posted: Apr 9 2014, 02:37 PM
  Quote Post


Posts: 10,109
Thanks: 299


QUOTE
keep the boys in their overpaid jobs, then wait for the better science to gazump PBT with a fast track to market.


Final act left to play out.

Hate to say I told you so, but I told you so. grrr.gif






--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Mar 8 2014, 11:49 AM
  Quote Post


Posts: 10,109
Thanks: 299


The spruikers here often throw up the fact that because Tanzi is involved PBT must be a winner. The following highlights what Tanzi is currently working on. It addresses root cause of disease. Including AD.

QUOTE
Dr. Rudolph Tanzi is a Professor of Neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology and Mental Retardation at Harvard University. Dr. Tanzi currently spearheads the Alzheimer’s Genome Project, which recently identified four new AD gene candidates. This achievement was named one of the “Top Ten Medical Breakthroughs of 2008” by Time Magazine.

Tanzi is one of the ten most cited researchers in AD, having co-authored over 340 research articles. He is also a co-author of a popular trade book on Alzheimer’s disease entitled “Decoding Darkness: The Search for the Genetic Causes of Alzheimer’s Disease”.


Unless PBT are ahead of the competition in these gene therapies then they are not even in the race. I believe nothing in the pipeline is gene based.


Therefore PBT must be a pumped up dog with an empty bark. The only hope they have is CSIRO have licenced to them all the world class IP they have to make PBT a world leader in finding a cure for AD.







--------------------
What did Uncle Mel do to us?
 
joules mm1
post Posted: Mar 6 2014, 12:09 PM
  Quote Post


Posts: 1,353
Thanks: 359


release

"strategy validated"

https://content.markitcdn.com/CommSec/Api/D...jpudWxsfQ==.pdf



--------------------
. . . . . . . . everything has an art.....in the instance of the auction process, the only thing, needed to be listened to; price
 
joules mm1
post Posted: Mar 5 2014, 09:25 PM
  Quote Post


Posts: 1,353
Thanks: 359


here's a reason we're seeing a strong price but no strong (above zero) MoneyFlow (Twiggs) in either 21 day or 13 week
what that tends to suggest is a strong move on the news release and then covering of longs into chasing weak hands....

QUOTE
yeast-model-reveals-alzheimer-s-drug-candidate-and-its-mechanism-of-action


http://www.newswise.com/articles/yeast-mod...P17818s.twitter



the race is on



--------------------
. . . . . . . . everything has an art.....in the instance of the auction process, the only thing, needed to be listened to; price
 
 


50 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING